Return to program book search
Merkel Cell Carcinoma: Diagnosis, Management & Controversies
Friday, March 01
10:00 AM - 12:00 PM
Paul Nghiem, MD, PhD, FAAD
- Christopher K. Bichakjian, MD, FAAD
- Klaus J. Busam, MD
Following this course, the attendee should be able to:
- Identify areas of controversy and consensus regarding the risk factors; incidence; clinical, pathologic, and prognostic characteristics of Merkel cell carcinoma.
- Analyze data linking the Merkel cell polyomavirus and immune evasion by this cancer to outcomes and emerging therapies.
- Utilize this information to guide the multidisciplinary management of representative cases.
Merkel cell carcinoma (MCC) is a polyomavirus-associated skin cancer with a higher disease-associated mortality (~46%) than melanoma (~15%) and an increasing incidence of ~1600 cases/year in the US. Management is challenging because therapy is different in nature than for other skin malignancies and is controversial within the literature. Multi-disciplinary care involving surgery, radiation, and medical oncology is often indicated. This session will highlight areas of consensus and controversy in the viral etiology, clinical presentation, staging, pathology and evolving management of MCC. Representative and challenging cases will be presented to highlight treatment options and relevant data.
|Friday, March 01|
|10:00 AM||Introduction, Epidemiology, Staging / Dr. Nghiem|
|10:20 AM||Pathologic diagnosis, Features and Prognostic implications / Dr. Busam|
|10:45 AM||Surgery, Sentinel lymph node biopsy, Radiation, and Case examples / Dr. Bichakjian|
|11:15 AM||Merkel polyomavirus, immunity and future targeted therapies / Dr. Nghiem|
|11:40 AM||Questions and Answers / All faculty|